Erica Norey’s practice focuses on complex patent litigation under the Hatch-Waxman Act, interference proceedings, and patent due diligence. She has worked on cases involving a range of pharmaceutical products and medical conditions including antivirals, antipsychotics, calcimimetics, chronic kidney disease, hyperparathyroidism, HBV, and HCV. Ms. Norey is also experienced on issues relating to patent ownership, FDA practice and procedure, employment, contracts, copyright, eDiscovery, corporate acquisitions, and ADR.
While in law school, Ms. Norey was an Executive Case Comment Editor of the New York Law School Law Review.
Gilead Pharmasset LLC v. Idenix Pharmaceuticals, Inc. Interference
Helped secure judgment on behalf of Gilead in this second patent interference against Idenix for patents related to methods for treating HCV infection using nucleoside analogs. Idenix has asserted this same patent against Gilead in district court, alleging that the sale, offer for sale, and distribution of Gilead’s anti-HCV drug, Sovaldi®, will infringe. However, absent a favorable appeal from the interference, Idenix’s involved claims cannot be asserted, in view of the Board’s finding of unpatentability and cancellation of the claims.